If you're disciplined enough to track your training load and your sleep, you should know that testosterone therapy comes with a blood marker worth watching just as closely. Among the most important is what happens to your red blood cells over time.
Why testosterone touches your red blood cells at all
Testosterone is not only an androgen — it's a signal that nudges the body to make more red blood cells. It stimulates erythropoietin (the hormone that drives red cell production in bone marrow) and influences iron regulation, which together can raise your red cell mass [1][2]. For some people on therapy, that's a small, quiet shift. For others, the rise is meaningful enough that a provider takes notice.
The two numbers that capture this are hemoglobin (the oxygen-carrying protein inside red cells) and hematocrit (the percentage of your blood volume made up of red cells). When either climbs, your blood becomes thicker, or more viscous. That's the underlying concern: testosterone-related increases in hematocrit are the most common lab change seen with therapy, and they are dose-related and more common with injectable forms than transdermal ones [1][3].
This matters for high performers in particular. If you're training hard, sometimes mildly dehydrated, and tracking your edge, you want to understand the difference between a normal physiologic response and a number that warrants a conversation.
Source: [1] Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline, [3] FDA Drug Safety Communication: Testosterone products — labeling changes and monitoring
What "too high" actually looks like
Guidelines from the Endocrine Society describe erythrocytosis — an elevated red cell count — as a recognized adverse effect of testosterone therapy, and they build monitoring around it [1]. A commonly referenced threshold in clinical practice is a hematocrit above roughly 54%, at which point providers typically reassess the plan rather than continue unchanged [1][4].
It's worth being precise here: an elevated hematocrit on TRT is a *biomarker a provider manages*, not a verdict. The concern is that higher blood viscosity could, in theory, raise cardiovascular risk, though the clinical significance of testosterone-induced erythrocytosis is still an area of active study [2][3]. That uncertainty is exactly why monitoring exists — so an independent provider can act on data instead of guesswork.
% hematocrit · marker = Reassessment threshold
Source: [1] Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline, [4] Testosterone-induced erythrocytosis: evaluation and management
The monitoring rhythm a provider typically follows
This is where a responsive provider earns their keep. Endocrine Society guidance recommends checking hematocrit before starting therapy, then again at intervals during the first year, and periodically thereafter [1]. A baseline matters because some men already run on the higher end before any therapy — and you can't interpret a change you never measured.
A typical cadence many providers use:
- Baseline — hematocrit, hemoglobin, and testosterone before anything begins.
- Early follow-up — recheck within the first several months, when changes are most likely to appear.
- Ongoing — periodic checks at least annually once you're stable, more often if a number is trending up [1].
If hematocrit rises toward the threshold, a provider has several levers — re-evaluating the regimen, adjusting the approach, addressing contributing factors like dehydration or sleep apnea, or ordering more frequent labs. None of that is something to self-manage. The point of supervision is that the plan flexes with your data.
Source: [1] Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
Context that changes the picture
A single elevated reading isn't read in isolation. Providers consider the whole context:
- Hydration. If you came in dehydrated after a long run, hematocrit can read artificially high. Hydration status genuinely shifts the number.
- Sleep apnea. Untreated obstructive sleep apnea independently raises red cell production and can compound a testosterone effect — and testosterone therapy itself may worsen sleep apnea in some people [1][3].
- Altitude, smoking, and baseline physiology. All can push red cell mass up before therapy is ever a factor.
- Formulation and regimen. Injectable testosterone is more associated with erythrocytosis than transdermal preparations [3].
For the athlete reading this: endurance training and altitude exposure can already shift these markers, which is one more reason a baseline and a provider who knows your training context beat a one-size protocol.
Fertility deserves its own line
If protecting future fertility is a priority, this is a separate but critical conversation to have *before* starting. Exogenous testosterone suppresses the body's own signaling axis and can reduce sperm production — sometimes significantly — which is why fertility-conscious men discuss this openly with an independent provider before any decision [1][5]. There are different management strategies, and the right approach depends entirely on your goals and your provider's clinical judgment. The lesson from a friend's botched gray-market cycle is the right one: do this with labs, oversight, and a plan, not a vial and a guess.
The estrogen piece, briefly
For the optimizer thinking about the full hormone picture: testosterone is converted to estradiol via the aromatase enzyme, so estrogen is part of the same system, not a side issue [1]. Whether and how estradiol is monitored or managed is a clinical decision an independent provider makes based on your labs and symptoms — not something to chase on your own. The principle is the same as with hematocrit: measure, interpret in context, adjust responsively.
What rising numbers signal — and what they don't
A gradual, mild rise in hematocrit that stays within range is common and expected. A steeper climb, or a number crossing the threshold, is the signal to slow down and reassess. It does not automatically mean stopping therapy — it means a provider gathers more information and decides the next step. That responsiveness, checking again rather than waiting a year, is the difference between thoughtful supervision and set-and-forget care.
The takeaway for anyone serious about doing this well: hematocrit and hemoglobin aren't obstacles to optimization. They're the dashboard that lets a provider keep the plan safe while you keep pursuing performance.
*This article is educational and is not medical advice. Lab targets, monitoring frequency, and any treatment decisions are made by an independent licensed provider based on your individual evaluation.*
Where Velri fits
Velri is a technology and coordination company — not a medical practice. We help coordinate the pieces: convenient lab work so you and an independent provider can see your baseline and trends, a visit with an independent licensed provider who reviews your numbers in context, and — only if that provider determines it's appropriate — fulfillment through an independent licensed pharmacy. A prescription is never guaranteed; it is decided by the independent provider.
Where a provider discusses compounded medications: compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
